

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

<p>(51) International Patent Classification ⁵ : A61M 1/36</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/25086</p> <p>(43) International Publication Date: 10 November 1994 (10.11.94)</p>		
<p>(21) International Application Number: PCT/US94/01107</p> <p>(22) International Filing Date: 15 February 1994 (15.02.94)</p> <p>(30) Priority Data: 08/053,734 27 April 1993 (27.04.93) US</p> <p>(71) Applicant: HAEMONETICS CORPORATION [US/US]; 400 Wood Road, Braintree, MA 02184 (US).</p> <p>(72) Inventors: LATHAM, Allen, Jr.; 143 Whitcomb Avenue, Jamaica Plain, MA 02130 (US). JORGENSEN, Glen, E.; 38 Beverly Drive, Marlborough, MA 01752 (US). SIBINGA, Theodoor, Henri, Smit; 72 St. Stephen Street, No. 4, Boston, MA 02115 (US). PLANTE, Joseph, R.; 21-11 Stoney Brook Drive, Millis, MA 02054 (US). KNAPP, Tracey, E.; 231 Webster Street, Hanover, MA 02339 (US).</p> <p>(74) Agents: REYNOLDS, Leo, R. et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).</p>		<p>(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		

The diagram illustrates a blood processing system 10. It starts with a Donor line (24) that branches into two paths. One path goes through a Blood Filter (F1) and a DPM (M1) to a valve (V1). The other path goes through a DPM (M2) and a valve (V2). Both paths lead to a Draw/Return Pump (P1) and a Recirc. Pump (P2). The system also includes an ACD Pump (P3) and an ACD (16). A Bowl (11) is connected to the system, with Bowl Optics (21) and PT1 and PT2 sensors. The system further includes a Plasma/Air Bag (18), a Platelet Bag (20), and a WBC Bag (22). Various valves (V1-V6) and sensors (PT1, PT2) are shown. The system is labeled 10.

An apheresis apparatus and method is disclosed for increasing the purity and yield of platelets separated from donated whole blood in a centrifuge (11). The whole blood in the centrifuge (11) is diluted by recirculating fluid, such as plasma or saline, at a first flow rate, to mix with further withdrawn whole blood prior to entering the centrifuge. As plasma is collected (in plasma/air bag (18)), it is recirculated (via line 40) through the centrifuge (11) at a second flow rate to further improve the separation between the intermediate density components, i.e., platelets and white blood cells in the "buffy coat". The plasma is then recirculated through the centrifuge at a third flow rate and platelets are displaced out of the centrifuge while the plasma is recirculating through the centrifuge at the third flow rate.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

APHERESIS APPARATUS AND METHODBACKGROUND OF THE INVENTION

With the advance of medical science, the demand for platelet concentrates with low contamination of white
5 blood cells (WBC), such as, lymphocytes is rapidly growing. Platelets are fragments of a large cell located in the marrow called a megakaryocyte. Platelets have no nucleus and are primarily responsible for hemostasis, although they also have a role in tissue healing. They
10 interact to chemicals released from damaged endothelial cells by becoming "sticky" and adhering to the damaged tissue. Platelets then release ADP, a chemical, which causes other platelets to stick to each other. This action, also known as aggregation, forms the primary white
15 clot. Platelets then activate plasma proteins responsible for clotting which produce the "red" clot or the stable clot. Platelets have a half-life of 4 - 6 days in the normal adult. Normal platelet counts are 150,000 - 400,000/mm³ in the adult. Platelet counts under
20 20,000/mm³ can result in spontaneous bleeding.

With the improvement in cancer therapy patients are requiring increased platelet support. In addition, with the large number of screening tests employed for blood products, the number of units that are acceptable are less
25 than in past years. The donor pool is reduced and therefore, the supply of random donor platelets must be conserved.

Procedures for collection of specific blood components from a single blood donor, apheresis, is proven
30 to be a satisfactory approach to cover the demand for blood components. Recently, the equipment for collection of platelets has been directed towards maximizing the yield of pure platelets. (See for example, U.S. 4,416,654.) Today, it is understood that the

-2-

contamination of platelet concentrates by WBC can lead to medical complications, such as graft-versus-host reactions.

Current blood separation equipment for the collection
5 of platelet concentrates are not sufficient for automatically collecting an optimum pure platelet concentrate.

Accordingly, there is a continuing need for an apheresis separation apparatus and method for
10 automatically collecting platelet concentrates with low white blood cell contamination while maximizing platelet yields.

SUMMARY OF THE INVENTION

The present invention provides a pheresis apparatus
15 and method for increasing blood component yield from donated whole blood in a centrifugation fractionation volume. In accordance with the invention, whole blood is diluted by recirculating lower density fluid, preferably plasma, at a first flow rate, to mix with further
20 withdrawn whole blood prior to entering the centrifuge. The diluted whole blood enters the fractionation or separation volume through an inlet port and is separated by centrifugation in the volume into a lower density components and higher density components. The higher
25 density components are mainly red blood cells, white blood cells and platelets. The lower density component is mainly plasma.

During separation, lower density component is displaced from the volume through an outlet port to a
30 first container. The blood pump is stopped and the collected lower density component is then returned to the separation volume through the inlet port at a second flow rate. The second flow rate is greater than the first flow

-3-

through a "buffy coat" (made up of white blood cells and platelets), thereby diluting and widening the "buffy coat". The widened "buffy coat" improves the separation between white blood cells and platelets by allowing the denser white blood cells to sediment from the lighter platelets more completely to the outer layers of the buffy coat. In this manner, the separation of the higher density components remaining in the volume is improved. The improved separation between the white blood cells and platelets reduces the amount of white blood cell contamination when the platelets are finally collected.

The lower density component is then recirculated again through the volume at a third flow rate and component with density between lower density component and higher density components (the platelets) are displaced out of the volume while the lower density component is recirculating through the volume at the third flow rate. The third flow rate is at a rate greater than the second flow rate.

Blood components displaced from the volume are monitored by an optical line sensor which determines the specific component being displaced by the optical density of the component. An uninterrupted conduit or passageway is in fluid communication with the outlet port and extends from the outlet port beyond the optical line sensor. The optical line sensor is positioned intermediate the outlet port of the volume and the first container for collecting low density component.

An uninterrupted passageway prevents foam accompanying components displaced from the volume from being mixed more thoroughly with the components, thereby preventing false optical readings by the optical line sensor.

-4-

The present invention provides an apheresis apparatus and method for collecting platelet concentrates with lower white blood cell contamination than with existing apparatus and methods while maximizing platelet yields.

- 5 The lower white blood cell contamination decreases exposure to viruses and possible alloimmunization.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred
10 embodiments of the drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the
15 principles of the invention.

Figure 1A is a schematic drawing of a preferred embodiment of the apparatus of the present invention.

Figure 1B is a schematic drawing of a disposable system for use with the apparatus of Figure 1A.

- 20 Figure 2 is a graph showing recirculation pump speed in ml/min (curve a) and line sensor output values (curve b) at different stages of the blood separation process for a three pump apparatus of Figures 1A and 1B of the invention.

- 25 Figure 3 is a side view of a centrifuge bowl with a section broken away and connected to an optical line sensor 14.

- Figure 4 is a plan view of a prior art apheresis apparatus showing a Y-connector upstream of the optical
30 sensor 14.

Figure 5 is a plan view of the present invention showing a T-connector downstream of the optical sensor 14.

-5-

Figure 6 is a schematic drawing of a two pump preferred embodiment of the present invention.

Figure 7 is a graph showing pump speeds at different stages of blood separation for a two pump apparatus of the invention.

Figures 8A and 8B are a processing flow chart of a protocol for a 3-pump embodiment of the invention.

Fig. 9 is a plot of the output of lines sensor 14 versus time.

10 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring now to Figures 1A and 1B, an apheresis system 10 uses a standard Latham type centrifuge 11 similar to the centrifuge described in U.S. Patent Number 3,145,713 (incorporated herein by reference) for separating anticoagulated whole blood into its constituent components. The centrifuge 11 consists of a rotatable bowl 12 and stationary input and output ports PT1 and PT2 fluidly coupled to the bowl interior by a rotary seal 74 (see Figure 3). An input port PT1 of centrifuge 11 is in fluid communication with phlebotomy needle 24 via blood filter F1, tubing 28 and Y-connector 30 when valve V1 is open. Tubing 28 is formed of blood compatible tubing as is all the tubing in apparatus 10. An outlet port PT2 of centrifuge 11 is selectively coupled by valve V2 and tubing 36, 37 with a first container 18 labelled plasma/air bag suspended from weight scale 33. A second container 20 labelled platelet bag is selectively coupled via valve V3 and tubing 39, 36 to outlet port PT2.

A third container 16 for storing anticoagulant, is in fluid communication with phlebotomy needle 24 via filter F2, tubing 32 and Y-connector 30. Bacterial filter F2 prevents any bacteria in the anticoagulant (ACD) container 16 from entering the system. Containers 16, 18 and 20 are preferably plastic bags made of blood compatible material. Peristaltic pumps P1, P2 and P3, together with valves V1,

-6-

V2 and V3, control the direction and duration of flow through apparatus 10 in response to signals generated, by line sensor 14, donor pressure monitor (DPM) M1, system pressure monitor (SPM) M2 and air detectors D1, D2 and D3.

5 Air detectors D1, D2 and D3 detect the absence or presence of fluid. Pressure monitors M1 and M2 monitor pressure levels within apparatus 10. Line sensor 14 is an optical sensor which detects the presence of blood components passing through line sensor 14 from output port PT2.

10 In initial operation, pumps P1 and P3 are energized to prime tubing 28 of apparatus 10 with anticoagulant from container 16. The anticoagulant passes through filter F2 and Y-connector 30 before reaching air detector D1. Air detector D1 senses the presence of anticoagulant at D1 and
15 terminates the anticoagulant priming operation. During the priming operation, valve V2 is open and sterile air displaced from bowl 12 by the anticoagulant enters the top port PT3 of air/plasma container 18.

Phlebotomy needle 24 is then inserted into the donor
20 and the DRAW stage is commenced. The DRAW stage is the first stage in a sequence of 4 stages; DRAW, DWELL, SURGE and RETURN (see Figure 2) performed by apparatus 10 when separating blood components. The pump speed for recirculation pump P2 during the DRAW, DWELL, and SURGE
25 stages is graphically shown in curve a of Figure 2. During DRAW, whole blood is drawn from the donor at a rate of about 80 ml/min and mixed with anticoagulant using pumps P1 and P3. Pump P3 mixes anticoagulant from container 16 with the whole blood drawn from the donor.
30 Valve V1 is open allowing anticoagulated whole blood to pass through tubing 28 and blood filter F1 before being pumped into bowl 12 through inlet port PT1. The whole blood is coupled to the bottom of the bowl 12 through a

-7-

feed tube (not shown). The ratio of the anticoagulant to whole blood is typically about 1:10.

Referring to Figure 3, centrifuge 11 has a fixed inlet port PT1 and a fixed outlet port PT2. A rotary seal 5 74 fluidly couples the stationary inlet port PT1 to the lower interior portion of the bowl 12, and the outlet port P2 to an upper portion of the bowl interior for collecting separated fractions. A core 72 occupies a coaxial volume of the interior of bowl 12 and provides a separation 10 volume between the coaxial wall of core 72 and the outer bowl wall 70.

As bowl 12 is rotated, centrifugal forces separate the anticoagulated whole blood admitted into the bottom of the bowl into red blood cells (RBC), white blood cells 15 (WBC), platelets and plasma. The blood is separated into different fractions in accordance with the component densities. The higher density components, i.e. RBCs 60, are forced to the outer wall 70 of bowl 12 while the lighter density plasma 66 lies nearer the core 72. A 20 "buffy coat" 61 is formed between the plasma 66 and the RBCs 60. The "buffy coat" 61 is made up of an inner layer of platelets 64, a transitional layer 68 of platelets and WBCs and an outer layer of WBCs 62. The plasma 66, being the component closest the exit port from the separation 25 volume, is the first fluid component displaced from bowl 12 via port PT2 as additional anticoagulated whole blood enters bowl 12 through port PT1.

Returning to Figure 1A, the exiting plasma passes through line sensor 14, tubing 36, 3-way T-connector 26 30 and valve V2 (in the open position) before entering air/plasma container 18. Plasma entering air/plasma bag 18 is drawn from container 18 by recirculate/surge pump P2 and is recirculated at about 20-30 ml/min into bowl 12 through port PT1. The recirculated plasma dilutes the

-8-

anticoagulated whole blood entering bowl 12 and allows the blood components to separate more readily. The equation for optimum recirculation rate is as follows:

$$Qr = Qc - \left[\left[1 + \left[\frac{Hd}{100} \right] \cdot (ACD - 1) \right] \right] \cdot Qd$$

where,

- 5 Qr = recirculation flow rate (ml/min.)
 Qc = critical flow rate (ml/min.)
 Hd = donor hematocrit (%)
 ACD = ACD/anticoagulated whole blood ratio
 Qd = Draw flow rate (ml/min.)

- 10 A critical flow rate of between 60 and 80 ml/min. has been shown to be effective at keeping platelet separated from WBC's. When a bowl optical sensor 21 senses the "buffy coat" is at a particular radius called the "surge" radius (≈ 3.81 cm), the DRAW cycle is completed. Valve V1
 15 is closed, pump P1 is stopped so blood is no longer drawn from the donor and the DWELL stage is commenced.

- During DWELL, pump P2 recirculates plasma 66 through bowl 12 at a moderate rate (about 100 ml/min as depicted in Figure 2) for about 20-25 sec. (331-354). At this flow
 20 rate, the "buffy coat" 61 widens but the platelets do not leave bowl 12. The lowered concentration of particles in the "buffy coat" allows the heavier white cells to sediment to the outer side of the "buffy coat". The recirculated plasma maintains a constant flow rate of
 25 dilutant through the "buffy coat" (in the direction of the arrows) and results in a better separation between the lighter platelet layer 64 and the heavier white blood cell layer 62. As a result, the transitional layer 68 is

-9-

reduced. The DWELL period also allows the flow patterns in bowl 12 to stabilize and allows more time for micro-bubbles to leave bowl 12 and be purged.

After DWELL, the SURGE stage is commenced. In SURGE, the speed of pump P2 (starting at 100 ml/min) is increased in 10 ml/min increments to recirculate plasma until reaching a platelet surge velocity of about 200 ml/min. The platelet surge velocity is the velocity at which platelets can leave bowl 12 but not red blood cells or white blood cells. The plasma exiting the bowl becomes cloudy with platelets and this cloudiness is detected by line sensor 14 (See Figure 2, curve b) and the output of the detector decreases at point A. Line sensor 14 consists of an LED which emits light through blood components leaving the bowl 12 and a photo detector which receives the light after it passes through the components. The amount of light received by the photo detector is correlated to the density of the fluid passing through the line.

When platelets first start leaving the bowl 12, the line sensor output starts to decrease. At point A in curve b, Figure 2, valve V3 is opened and valve V2 closed and the platelets are collected in container 20. Once the majority of the platelets are removed, from bowl 12, the fluid exiting the bowl becomes less cloudy. This lessening of cloudiness is detected by line sensor 14 and the line sensor output bottoms out at the inflection point B. At this point the total depth of the curve is taken, and the machine waits until the sensor signal rises for a given percentage, point C. At this point of time, the valve V3 is closed and the collection ended, or collection of white cells initiated.

Optionally, at this point C, collection of WBC may be started as indicated in Figure 1A, utilizing an additional

-10-

valve V4 and a third collection container, WBC bag 22 (shown in dotted lines in Figure 1A). After the line sensor output has reached its minimum, inflection point B, the fluid starts to clear out. Once the sensor output has risen a given percentage, relative to the total depth of the curve, point C is reached and valve V3 is closed, valve V4 is opened and the recirculation pump further increases its speed to the lymphocyte surge rate. This initiates the collection of WBC. The line sensor will soon reach a maximum; the deflection point D. Once the deflection point has been reached, the cloudiness of the fluid will start to increase again as larger particles start to leave the bowl. The machine now waits for the sensor signal to drop to a given percentage of the original line sensor reference value; point E. At this point red cells start leaving the bowl and valve V4 is closed and collection is ended.

After the platelets and/or WBC have been collected, apparatus 10 begins the RETURN stage. During return, the rotation of bowl 12 is stopped and the remaining blood components in bowl 12 are returned to the donor (by reversal of rotation of pump P1) via phlebotomy needle 24 with valve V1 open. V2 is also opened to allow air to enter the centrifuge bowl during return. Plasma from container 18 dilutes the remaining blood components in bowl 12. Pump P2 mixes the plasma with the returning components in bowl 12 with valve V2 open diluting the returned components to speed up the return time. When the remaining blood components in the bowl have been returned to the donor, the RETURN stage is terminated and the phlebotomy needle 24 may be removed from the donor.

Depending upon the amount of platelets needed, this process of DRAW, DWELL, SURGE and RETURN can be performed multiple times.

-11-

During DRAW, the anticoagulated whole blood entering bowl 12 can be diluted with a solution such as saline from a container 90 (shown in dotted lines) instead of plasma using V6, V5, and pump P2.

5 An alternative two pump embodiment 50 of the present invention is shown schematically in Figure 6. Apparatus 50 uses two pumps, draw/return pump P1 and an anticoagulant pump P3.

10 In operation, apparatus 50 is primed in the same manner as previously discussed. Apparatus 50 also performs the DRAW, DWELL, SURGE and RETURN stages in a similar manner to that of apparatus 10. Figure 7 graphically shows the pump speeds for pump P1 for the DRAW, DWELL and SURGE stages. During the DRAW stage, 15 whole blood is drawn from a donor and mixed with anticoagulant using pumps P1 and P3. Valve V1 is open, allowing anticoagulated whole blood to pass through tubing 28 and blood filter F1 before being pumped into bowl 12 through inlet port PT1. Bowl 12 is rotated, separating 20 the anticoagulated whole blood into different fractions. The least dense component, i.e. plasma 66, is the first displaced from bowl 12 via port PT2 as additional anticoagulated whole blood enters bowl 12 through port PT1. The plasma passes through tubing 36, is sensed by 25 line sensor 14 and completed through T-connector 26 and through valve V2 (in the open position) and enters container 18. Valve V5 is closed, permitting the plasma to collect in container 18. After the bowl optics 21 sense the "buffy coat" is at the proper position, valve V1 30 closes, terminating the DRAW stage.

Apparatus 50 then begins the DWELL stage. During DWELL, pump P1 pumps collected plasma from container 18 (with valve V5) open into bowl 12 through tubing 34 and port PT1 at an elevated rate of 120 ml/min for a period of

-12-

about three seconds before dropping to a moderate 75 ml/min for about 27 more seconds (Figure 7). The plasma 66 flows through the "buffy coat" and dilutes it. The three second period of elevated flow rate thus widens the thickness of "buffy coat" thereby providing a better separation between platelets and WBCs. The remaining period at the moderate flow rate stabilizes the flow patterns in bowl 12. After DWELL, pump P1 increases the flow rate of the recirculating plasma at the rate of 8 (ml/min)/sec until reaching the maximum surge velocity of 200 ml/min (Figure 7). At the maximum surge velocity, platelets (Figure 3) begin to exit bowl 12. The plasma exiting the bowl 12 becomes cloudy with platelets and this cloudiness is detected by line sensor 14. Line sensor 14 causes valve V3 to open and the platelets are collected in container 20. After the platelets have been removed from bowl 12, line sensor 14 detects the absence of platelets and closes valve V3.

Optionally the WBC collection stage can be commenced using values V4 and WBC by 22 (shown in dotted lines) after which the RETURN stage is commenced. The rotation of bowl 12 is slowed and the remaining blood components in bowl 12 are returned to the donor by pump P1 via phlebotomy needle 24.

Figure 4 depicts a prior art product sold by Haemonetics Corporation under the name Mobile Collection System (MCS). This system 10' physically is similar to the present system and has the surge capability of the prior out patient referenced supra. In this system the branching connector 26' is located upstream of the optical sensor 14'. Outlet port P2' is in fluid communication with tubing 36' and Y-connector 26'. One branch of tubing 36' passes through optical sensor 14. M2 is coupled directly to pressure monitor M2' via tubing 38'. This

-13-

prior art location of Y-connector 26' causes foam, which is floating on the surface of blood components leaving bowl 12 through port PT2 to substantially mix with the separated components. The mixing of the foam with the components results in false readings from the optical line sensor 14 because the mixed foam scatters light emitted by the LED of line sensor 14 so that the photo detector does not receive the correct amount of light associated with the specific blood component exiting bowl 12. False reading can cause less than optimal component collection i.e., less platelets are collected than is desired.

Figure 5 depicts the location of a T-connector 26 downstream of line sensor 14 in the apparatus 10 of the present invention. As may be seen, T-connector 26 is disposed between the line sensor 14 and container 18 and monitor M2 ensuring that an uninterrupted length of tubing 36 is present between port PT2 and the line sensor 14. The uninterrupted tubing 36 reduces the possibility that foam floating on fluid exiting bowl 12 will be substantially mixed with the exiting fluid causing line sensor 14 to make false readings.

Referring back to Figure 1B and the disposable set depicted therein it should be noted that the length of tubing 36 between PT2 and T-connector 26 must be sufficient to permit T-connector 26 to extend downstream beyond the location of the line sensor 14 (Figure 5).

Furthermore, use of a so-called "chimney bag" 18 is recommended for the air/plasma application. Chimney bag 18 has a top port PT3 for introduction of air or plasma and a bottom port PT4 coupled via tubing to Y-junction 91 and either to input port PT1 for surge purposes or to phlebotomy needle 24 through filter F1 for fast return purposes. Sterile air from bowl 12 is stored temporarily in the air/plasma bag 18, rather than the conventional use

-14-

of an air/platelet bag for air storage. By entering the air into the plasma/air bag rather than the platelet bag, the lines 36, 37, 39 and 35 from the bowl 12 to the bags are cleaned out into the plasma bag. This means that any
5 contamination (i.e. WBC's) in the lines will not be drained into the platelet component product. This results in a lower white cell count of the platelet product.

In the DWELL and SURGE stages the chimney bag 18 operates as an air trap; this reduces foaming in the bowl
10 12 and thus more stable line sensor outputs.

Figures 8A and 8B are a processing flow chart indicating the major steps required to process blood and collect platelets in accordance with the apparatus of the invention. In the flow chart the following terms have the
15 meanings given in Table I below:

-15-

TABLE I

Term	Definition
B.O.	Bowl Optics
Ref.	reference
L.S.	line sensor
Recirc. speed	speed of recirculation pump
CLEAR B.O. REF	Bowl Optics voltage off empty bowl
AIR/PLASMA INTERFACE	Bowl Optics detects fluid
COLLECTING PLASMA	Plasma collected through plasma valve
B.O. REF. TAKEN	Bowl Optics voltage off plasma in bowl
L.S. REF. 1	Line sensor voltage off plasma taken during Draw cycle
DWELL	Draw pump stops. Plasma recirculated at 100 ml/min through bowl
L.S. REF. 2	Line sensor voltage off plasma taken during DWELL cycle
Start Collection	Close plasma valve. Open platelet valve. Start collecting platelets
Peak value	Lowest voltage value measured by line sensor

While the bowl is being filled a display on a control panel (100, Figure 5) displays "FILLING BOWL" and after 40 ml of anticoagulated whole blood has been pumped by pump P1 into bowl 12 a reading is taken using an optical
5 detector (called the Bowl Optics) located adjacent transparent centrifuge bowl 12. If this reading is less than 50% of an optically clear reference reading with the bowl empty; then the display indicates that fluid has been detected by displaying an AIR/PLASMA Interface signal. If
10 not, a new reading is taken (STEP1).

After another 55 ml has been pumped into the bowl the display indicates that plasma is now being collected and a plasma B.O. reading is taken of the plasma as it forms in the bowl (STEP2). If this reading is less than 80% of a

-16-

plasma reference reading then a line sensor reading is taken of the plasma during a draw cycle. If not, then step 2 is repeated.

After the line sensor reading is taken (STEP3)

- 5 another BO reading is taken until the bowl optics reading indicates that the value is less than 65% of the BO plasma reference reading, in which case, the DWELL stage is commenced (STEP4).

- After 25 sec. of DWELL a second line sensor reference
10 reading is taken (STEP5). At 30 sec. of DWELL, the line sensor reference 2 value is compared with the line sensor reference 1 value. If L.S. REF 2 is greater than 92% of the L.S. REF 1, then the L.S. REF. 2 value is used as a reference in the next step. If not, then the L.S. REF. 1
15 value is used (STEP 6).

- Next, the SURGE stage is entered by increasing the recirculation speed of Pump P2 in increments of 10 (ml/min)/sec and the line sensor reading is compared with the L.S. REF reading selected in STEP6. If the reading is
20 less than 95% of the reference value and the pump speed is greater than 150 ml/min platelet collection is commenced and timer T(1) is started (STEP 7).

- When the recirculation speed is equal to 200 ml/min the speed is kept constant at 200 ml/min. If T(1) is less
25 than or equal to 2 seconds and the slope of the Line Sensor curve (curve b of Figure 2) is greater than or equal to zero, the peak value of the LS curve is stored and timer T(2) is started. If T(1) is greater than 2 seconds and the LS slope is not greater than or equal to
30 zero, platelet collection is terminated (STEP 8).

Timer T(2) starts and runs until T(2) is equal to 1.5 second. If over 6 sampling intervals the L.S. output increases by less than +5 digital values over each interval then platelet collection is terminated. If not,

-17-

the collection is ended when 50% of the difference between the line sensor reference voltage and the line sensor minimum voltage is reached (STEP 9).

A simplified revision of the line sensor curve b is shown in Figure 9 to summarize the platelet collection process described above. In Figure 9 the output of line sensor 14 is plotted versus time for a typical platelet collection process in accordance with the invention. At point A a Line Sensor Reference voltage is taken from the average value calculated at 25-30 sec. into DWELL. Surge is commenced at point B. Platelet collection is commenced when the Surge Speed is greater than 150 ml/min., and the line sensor voltage is less than 95% of the Line Sensor Reference voltage. The slope reversal at point C is detected and the slope is monitored until it levels off or decreases in which case platelet collection is ended. If the slope is increasing then collection is continued until the Line Sensor voltage reaches 50% of the reference value.

While this invention has been particularly shown and described with references to the preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

-18-

CLAIMS

1. Apparatus comprising:
 - (a) a centrifuge for separating whole blood into lower density, intermediate density and higher density components;
 - (b) an enclosed fractionation volume in said centrifuge;
 - (c) an inlet port and an outlet port mounted on said centrifuge, the ports being in fluid communication with said fractionation volume;
 - (d) pump means for (i) causing the whole blood to flow into said inlet port at a predetermined rate and (ii) for causing separated lower density component of whole blood to be recirculated to the inlet port of said centrifuge for diluting and widening the region occupied by the remaining contents while continuing to collect the lower density component, and,
 - (e) a first container in selective fluid communication with said ports for collecting the lower density components from said outlet port and selectively returning said lower density component to said inlet port.
2. The apparatus of Claim 1 further comprising a second container for collecting a first intermediate density whole blood component from said outlet port.
3. The apparatus of Claim 2 further comprising a third container for collecting a second intermediate density whole blood component from said outlet port.

-19-

4. The apparatus of Claim 3 in which:
the lower density whole blood component is plasma;
the first intermediate density whole blood
5 component is platelets; and
the second intermediate density whole blood
component is white blood cells.
5. Apparatus for fractionating whole blood from a donor
into lower, intermediate, and higher density
10 components thereof comprising:
(a) a centrifuge having an enclosed
fractionation volume and an inlet port and an outlet
port in fluid communication with said fractionation
volume;
15 (b) a first pump for causing said whole blood to
flow into said inlet port at a predetermined rate;
(c) a first container for collecting lower
density whole blood component from said outlet port;
and
20 (d) a second pump for causing the lower density
component to be recirculated to the inlet port to
dilute the remaining contents while continuing to
collect lower density component and thereby widen a
region occupied by the intermediate density
25 components, the widened region improving the
separation between the intermediate components.
6. The apparatus of Claim 5 further comprising a second
container for collecting a first intermediate density
whole blood component from said outlet port.

-20-

7. The apparatus of Claim 6 further comprising a third container for collecting a second intermediate density whole blood component from said outlet port.
8. The apparatus of Claim 7 in which:
- 5 the lower density whole blood component is plasma;
- the first intermediate density whole blood component is platelets; and
- 10 the second intermediate density whole blood component is white blood cells.
9. Apparatus comprising:
- (a) a separation chamber for separating whole blood into lower density, intermediate density and higher density components;
- 15 (b) a stationary inlet port and a stationary outlet port mounted on said separation chamber, the ports being in fluid communication with said separation chamber;
- (c) a first container in fluid communication with said ports for collecting lower density components from said outlet port;
- 20 (d) a conduit for providing fluid communication between the outlet port and the first container; and
- (e) a line sensor for sensing fluid exiting the outlet port and wherein the fluid communication from the outlet port is unimpeded until after the fluid is
- 25 sensed by the line sensor.

-21-

10. The apparatus of Claim 9 in which the separation chamber is a rotary centrifuge bowl having a cone providing a fractionation volume between the cone and the bowl for separating the whole blood, the fractionation volume being fluidly coupled to the inlet and outlet ports by a rotary seal.
11. The apparatus of Claim 10 further comprising a multiport fluid junction located between the optical line sensor and the first container for collecting the lower density component.
12. The apparatus of Claim 11 further comprising a second container in selective fluid communication with the multiport fluid junction for collecting a first intermediate density whole blood component from said outlet port.
13. The apparatus of Claim 12 further comprising a third container in selective fluid communication with the multiport fluid junction for collecting a second intermediate density whole blood component from said outlet port.
14. The apparatus of Claim 13 in which:
the lower density whole blood component is plasma;
the first intermediate density whole blood component is platelets; and
the second intermediate density whole blood component is white blood cells.

-22-

15. A method of increasing intermediate density blood component yield from donated whole blood in a centrifugation fractionation volume comprising the steps of:
- 5 (i) diluting whole blood, by mixing fluid with the whole blood at a first flow rate as the blood is introduced into the volume;
- (ii) separating lower density component in the volume from higher density components in the volume and displacing a lower density component to a first container;
- 10 (iii) recirculating the lower density component to the volume at a second flow rate to further dilute the components remaining in the volume;
- 15 (iv) recirculating the lower density component through the volume at a third flow rate; and
- (v) displacing intermediate density component out of the volume while the lower density component is recirculating through the volume at the third flow rate.
- 20
16. The method of Claim 15 wherein the components remaining in the bowl after (v) are reinfused.
17. The method of Claim 15 wherein the second flow rate is greater than the first flow rate.
- 25 18. The method of Claim 15 wherein the third flow rate is greater than the second flow rate.
19. The method of Claim 15 further comprising collecting the intermediate density component in a second container.

-23-

20. The method of Claim 19 further comprising anticoagulating the whole blood with anticoagulant stored in a third container.
- 5 21. The method of Claim 20 further comprising displacing white blood cells out of the volume and collecting the white blood cells in a fourth container.
22. The method of Claim 15 in which the intermediate density component is platelets.
- 10 23. A method of increasing intermediate density component yield from donated whole blood in a centrifuge having an enclosed fractionation volume wherein:
- (i) pumping whole blood into the volume along a first flow route;
- 15 (ii) separating lower density component in the volume from higher density component in the volume and displacing the lower density component to a first container;
- (iii) closing the first flow route and opening the second flow route, and returning the lower
- 20 density component to the volume;
- (iv) recirculating the lower density component through the volume at a maximum flow rate; and
- (v) displacing intermediate density component
- 25 out of the volume while the lower density component is recirculating through the volume at the maximum flow rate.
24. The method of Claim 23 wherein the components remaining in the bowl after (v) are reinfused.

-24-

25. The method of Claim 23 wherein the second flow rate is greater than the first flow rate.
26. The method of Claim 23 wherein the third flow rate is greater than the second flow rate.
- 5 27. The method of Claim 23 further comprising collecting the intermediate density component.
28. The method of Claim 27 further comprising anticoagulating the whole blood with anticoagulant stored in a third container.
- 10 29. The method of Claim 28 further comprising displacing white blood cells out of the volume and collecting the white blood cells in a fourth container.
30. The method of Claim 23 in which the intermediate density component is platelets.
- 15 31. The method of Claim 23 wherein the lower density component initially returns to the volume at a slightly higher than moderate flow rate before falling to a moderate flow rate.
- 20 32. A method of increasing component yield from donated whole blood in a centrifuge having an enclosed fractionation volume wherein:
- (i) pumping anticoagulated whole blood into the volume;
- (ii) separating lower density component in the volume from higher density component in the volume and displacing the lower density component to a first container;
- 25

-25-

(iii) returning the lower density component to the volume at a moderate rate to dilute components remaining in the volume;

5 (iv) recirculating the lower density component through the volume at a maximum flow rate; and

(v) displacing component with density between lower density components and higher density components out of the volume while the lower density component is recirculating through the volume at the
10 maximum flow rate.

33. The method of Claim 32 wherein the components remaining in the bowl after (v) are reinfused.

34. The method of Claim 32 further comprising collecting the component between lower density component and
15 higher density component in a second container.

35. The method of Claim 34 further comprising anticoagulating the whole blood with anticoagulant stored in a third container.

36. The method of Claim 35 further comprising displacing
20 white blood cells out of the volume and collecting the white blood cells in a fourth container.

37. The method of Claim 32 in which the component with density between lower density component and higher density components are platelets.

25 38. The method of Claim 32 wherein the lower density component initially returns to the volume at a slightly higher than moderate flow rate before falling to a moderate flow rate.

-26-

39. The method of Claim 32 wherein the whole blood is diluted with lower density component recirculating at a low flow rate before reaching the volume.





FIG. 1A

2/11



3/11




FIG. 2

4/11




FIG. 3

5/11




FIG. 4
PRIOR ART

6/11




FIG. 5

7/11




FIG. 6

8/11





FIG. 7

9/11



10/11




FIG. 8B




FIG. 9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 94/01107

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61M1/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 155 684 (FRESENIUS AG) 25 September 1985 see page 4, line 16 - page 5, line 22 see page 7, line 1 - line 37 see page 10, line 19 - line 27 see page 12, line 1 - line 28 see page 15, line 35 - page 16, line 38 see figures 5A,5B	1-8
X	WO,A,87 06472 (JONSSON) 5 November 1987 see page 6, line 6 - page 10, line 6 see figure 2	1,2,5,6, 15-20, 22, 32-35,37
Y	---	21,23, 24, 27-30,36
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

10 August 1994

Date of mailing of the international search report

07.09.94.

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Schönleben, J

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 94/01107

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 416 654 (SCHOENDORFER ET AL.) 22 November 1983 cited in the application see column 4, line 7 - column 7, line 66 see figure 1	9-14
Y		21,23, 24, 27-30,36
A	----- US,A,3 957 197 (SARTORY ET AL.) 18 May 1976 see column 4, line 22 - line 27 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US 94/01107

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0155684	25-09-85	DE-A- 3410286 JP-A- 61022864 US-A- 4675117	03-10-85 31-01-86 23-06-87
WO-A-8706472	05-11-87	DE-A- 3785348 EP-A, B 0308407 EP-A- 0302879 JP-T- 1500087 JP-T- 1500170 WO-A- 8706471 US-A- 5098372 US-A- 5147290	13-05-93 29-03-89 15-02-89 19-01-89 26-01-89 05-11-87 24-03-92 15-09-92
US-A-4416654	22-11-83	US-A- 4464167	07-08-84
US-A-3957197	18-05-76	CA-A- 1080823 DE-A- 2617824 FR-A, B 2308380 GB-A- 1517874 JP-A- 51130962	01-07-80 04-11-76 19-11-76 12-07-78 13-11-76